41st Annual New Treatments in Chronic Liver Disease 2027

The 41st Annual New Treatments in Chronic Liver Disease 2027 presents the latest advances in diagnosing, managing, and treating chronic liver diseases through updated clinical evidence and expert insights.

Key Topics

• Hepatocellular carcinoma and liver mass evaluation
• Metabolic liver disease and non-alcoholic fatty liver disease
• Primary biliary cholangitis and primary sclerosing cholangitis
• Chronic hepatitis B, C, and Delta hepatitis
• Alcohol-related liver disease
• End-stage liver disease complications, including ascites, thrombocytopenia, and hepatorenal syndrome
• New therapeutic strategies and clinical trial data

Who should Attend

• Physicians and hepatologists
• Nurses, nurse practitioners, and physician assistants
• Gastroenterologists and transplant specialists
• Residents, fellows, and medical students
• Healthcare professionals involved in liver disease management